Cargando…

The chromogranin A-derived peptides catestatin and vasostatin in dogs with myxomatous mitral valve disease

BACKGROUND: The protein chromogranin A (CgA) is stored and co-released with catecholamines from the stimulated adrenal glands. Increased plasma concentrations of CgA have been shown in people with heart disease. The aim of the study was to investigate whether plasma concentrations of the CgA-derived...

Descripción completa

Detalles Bibliográficos
Autores principales:	Höglund, Katja, Häggström, Jens, Höglund, Odd Viking, Stridsberg, Mats, Tidholm, Anna, Ljungvall, Ingrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405357/ https://www.ncbi.nlm.nih.gov/pubmed/32758260 http://dx.doi.org/10.1186/s13028-020-00541-3

Ejemplares similares

Catestatin and vasostatin concentrations in healthy dogs
por: Srithunyarat, Thanikul, et al.
Publicado: (2017)

Decreased plasma Chromogranin A361-372 (Catestatin) but not Chromogranin A17-38 (Vasostatin) in female dogs with bacterial uterine infection (pyometra)
por: Jitpean, Supranee, et al.
Publicado: (2015)

Diagnostic Value of Selected Echocardiographic Variables to Identify Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease
por: Tidholm, A., et al.
Publicado: (2015)

Comparison between real‐time 3‐dimensional and 2‐dimensional biplane echocardiographic assessment of left atrial volumes in dogs with myxomatous mitral valve disease
por: Tidholm, Anna, et al.
Publicado: (2019)

Catestatin, vasostatin, cortisol, and pain assessments in dogs suffering from traumatic bone fractures
por: Srithunyarat, Thanikul, et al.
Publicado: (2017)

Chromogranin A and cortisol at intraoperative repeated noxious stimuli: Surgical stress in a dog model
por: Höglund, Odd Viking, et al.
Publicado: (2015)

Real‐Time 3‐Dimensional Echocardiographic Assessment of Effective Regurgitant Orifice Area in Dogs With Myxomatous Mitral Valve Disease
por: Tidholm, A., et al.
Publicado: (2017)

Measurement of catestatin and vasostatin in wild boar Sus scrofa captured in a corral trap
por: Fahlman, Åsa, et al.
Publicado: (2021)

Catestatin, vasostatin, cortisol, temperature, heart rate, respiratory rate, scores of the short form of the Glasgow composite measure pain scale and visual analog scale for stress and pain behavior in dogs before and after ovariohysterectomy
por: Srithunyarat, Thanikul, et al.
Publicado: (2016)

Chromogranins can be measured in samples from cats and dogs
por: Stridsberg, Mats, et al.
Publicado: (2014)

Serotonin Concentrations in Platelets, Plasma, Mitral Valve Leaflet, and Left Ventricular Myocardial Tissue in Dogs with Myxomatous Mitral Valve Disease
por: Cremer, S.E., et al.
Publicado: (2014)

Prevalence and Prognostic Importance of Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease
por: Borgarelli, M., et al.
Publicado: (2015)

Holter Monitoring of Small Breed Dogs with Advanced Myxomatous Mitral Valve Disease with and without a History of Syncope
por: Rasmussen, C.E., et al.
Publicado: (2014)

Effect of feline characteristics on plasma N‐terminal‐prohormone B‐type natriuretic peptide concentration and comparison of a point‐of‐care test and an ELISA test
por: Hanås, Sofia, et al.
Publicado: (2020)

Influence of clinical setting and cat characteristics on indirectly measured blood pressure and pulse rate in healthy Birman, Norwegian Forest, and Domestic Shorthair cats
por: Hanås, Sofia, et al.
Publicado: (2021)

Blood pressure and heart rate during ovariohysterectomy in pyometra and control dogs: a preliminary investigation
por: Höglund, Odd Viking, et al.
Publicado: (2016)

ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs
por: Keene, Bruce W., et al.
Publicado: (2019)

Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study
por: Boswood, Adrian, et al.
Publicado: (2020)

Plasmatic Dimethylarginines in Dogs With Myxomatous Mitral Valve Disease
por: Valente, Carlotta, et al.
Publicado: (2021)

Cardiac troponin I in healthy Norwegian Forest Cat, Birman and domestic shorthair cats, and in cats with hypertrophic cardiomyopathy
por: Hanås, Sofia, et al.
Publicado: (2022)

Occurrence of cardiorespiratory diseases and impact on lifespan in Swedish Irish Wolfhounds: a retrospective questionnaire-based study
por: Orleifson, Lovisa, et al.
Publicado: (2017)

Myxomatous degeneration of the mitral valve
por: Neto, Felippe Lazar, et al.
Publicado: (2018)

Biopterin Status in Dogs with Myxomatous Mitral Valve Disease is Associated with Disease Severity and Cardiovascular Risk Factors
por: Reimann, M.J., et al.
Publicado: (2014)

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial
por: Boswood, A., et al.
Publicado: (2016)

The genetic consequences of dog breed formation—Accumulation of deleterious genetic variation and fixation of mutations associated with myxomatous mitral valve disease in cavalier King Charles spaniels
por: Axelsson, Erik, et al.
Publicado: (2021)

Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease
por: Kim, H.‐S., et al.
Publicado: (2016)

Assessment of heart rate turbulence in dogs with myxomatous mitral valve disease
por: dos Santos, Julio P., et al.
Publicado: (2021)

Pro-Inflammatory and Immunological Profile of Dogs with Myxomatous Mitral Valve Disease
por: Piantedosi, Diego, et al.
Publicado: (2022)

Correction: The genetic consequences of dog breed formation—Accumulation of deleterious genetic variation and fixation of mutations associated with myxomatous mitral valve disease in cavalier King Charles spaniels
por: Axelsson, Erik, et al.
Publicado: (2022)

Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration
por: Reimann, M.J., et al.
Publicado: (2017)

Hemodynamic Effects of Protamine Infusion in Dogs with Myxomatous Mitral Valve Disease Undergoing Mitral Valvuloplasty
por: Yoshida, Tomohiko, et al.
Publicado: (2022)

The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs
por: Vezzosi, Tommaso, et al.
Publicado: (2021)

Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364–384))
por: Biswas, Nilima, et al.
Publicado: (2010)

Predictive model for the detection of pulmonary hypertension in dogs with myxomatous mitral valve disease
por: MIKAWA, Shoma, et al.
Publicado: (2014)

Reliability of symmetric dimethylarginine in dogs with myxomatous mitral valve disease as kidney biomarker
por: Savarese, Alice, et al.
Publicado: (2018)

Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs
por: Nakamura, K., et al.
Publicado: (2017)

Prevalence and risk factors for atrial fibrillation in dogs with myxomatous mitral valve disease
por: Guglielmini, Carlo, et al.
Publicado: (2020)

Radiographic quantification of left atrial size in dogs with myxomatous mitral valve disease
por: Lam, Christopher, et al.
Publicado: (2021)

Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs
por: Rešetar Maslov, Dina, et al.
Publicado: (2023)

Evaluation of progression of chronic kidney disease in dogs with myxomatous mitral valve disease
por: Yun, Hyejin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fji4t6h39iod7mla39bfujk36u